RECRUITINGOBSERVATIONAL
SV2 PET Imaging With [11C]APP311
Synaptic Density in Psychiatric Disorders Using SV2A Receptor PET Imaging With [11C]APP311
About This Trial
The aim of this study is to evaluate a new SV2A tracer, \[11C\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.
Who May Be Eligible (Plain English)
Who May Qualify:
- Willing and able to give voluntary written willing to sign a consent form
- Male and Female subjects, age 18 to 65 years, inclusive
Who Should NOT Join This Trial:
- MRI metal exclusions and claustrophobia.
- Education completed is less than 12 years
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Willing and able to give voluntary written informed consent
* Male and Female subjects, age 18 to 65 years, inclusive
Exclusion Criteria:
* MRI metal exclusions and claustrophobia.
* Education completed is less than 12 years
Treatments Being Tested
DRUG
[11C]APP311
It has been shown that radiotracer \[11C\]APP311 (aka \[11C\]UCB-J) displays high specificity and selectivity for the synaptic vesicle protein SV2A. Since this protein is expressed ubiquitously in active synapses, this tracer has the potential to be a general purpose tool for quantitative imaging of synaptic density.
Locations (1)
Conneticut Mental Health Center
New Haven, Connecticut, United States